Search research articles
Contact Us
Filters
Showing results (11-20 of 23) with videos related to
Page
of 3
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
November 6, 2022
The oncological multidimensional prognostic index is a promising decision-making tool: A real-world analysis in older patients with metastatic colorectal cancer
Letizia Procaccio, Francesca Bergamo, Maura Gatti, et al.
Cancer Chemotherapy and Pharmacology
|
September 19, 2023
Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes
Anna Maria Militello, Giulia Orsi, Alessandro Cavaliere, et al.
British Journal of Cancer
|
November 23, 2021
Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: a translational objective of the Valentino study
Paolo Manca, Salvatore Corallo, Sara Lonardi, et al.
Cancers
|
May 28, 2022
Simultaneous Care in Oncology: A 7-Year Experience at ESMO Designated Centre at Veneto Institute of Oncology, Italy
Antonella Brunello, Antonella Galiano, Stefania Schiavon, et al.
Cancer Medicine
|
June 6, 2023
The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma
Letizia Procaccio, Valeria Merz, Morena Fasano, et al.
Lancet (London, England)
|
November 23, 2025
Preoperative mFOLFIRINOX versus PAXG for stage I-III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2 × 2 factorial phase 3 trial
Michele Reni, Marina Macchini, Giulia Orsi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 6, 2021
The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer
Paolo Manca, Salvatore Corallo, Adele Busico, et al.
Frontiers in Oncology
|
July 30, 2019
High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib
Alessio Amatu, Marta Schirripa, Federica Tosi, et al.
Cancer Medicine
|
June 26, 2024
Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as second or later-line treatment
Guido Giordano, Michele Milella, Matteo Landriscina, et al.
The Oncologist
|
March 19, 2026
Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes and AI-guided treatment selection
Letizia Procaccio, Guido Giordano, Federico Nichetti, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 23) with videos related to
Sort By:
Page
of 3
European Journal of Cancer (Oxford, England : 1990)
|
November 6, 2022
The oncological multidimensional prognostic index is a promising decision-making tool: A real-world analysis in older patients with metastatic colorectal cancer
Letizia Procaccio, Francesca Bergamo, Maura Gatti, et al.
Cancer Chemotherapy and Pharmacology
|
September 19, 2023
Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes
Anna Maria Militello, Giulia Orsi, Alessandro Cavaliere, et al.
British Journal of Cancer
|
November 23, 2021
Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: a translational objective of the Valentino study
Paolo Manca, Salvatore Corallo, Sara Lonardi, et al.
Cancers
|
May 28, 2022
Simultaneous Care in Oncology: A 7-Year Experience at ESMO Designated Centre at Veneto Institute of Oncology, Italy
Antonella Brunello, Antonella Galiano, Stefania Schiavon, et al.
Cancer Medicine
|
June 6, 2023
The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma
Letizia Procaccio, Valeria Merz, Morena Fasano, et al.
Lancet (London, England)
|
November 23, 2025
Preoperative mFOLFIRINOX versus PAXG for stage I-III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2 × 2 factorial phase 3 trial
Michele Reni, Marina Macchini, Giulia Orsi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 6, 2021
The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer
Paolo Manca, Salvatore Corallo, Adele Busico, et al.
Frontiers in Oncology
|
July 30, 2019
High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib
Alessio Amatu, Marta Schirripa, Federica Tosi, et al.
Cancer Medicine
|
June 26, 2024
Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as second or later-line treatment
Guido Giordano, Michele Milella, Matteo Landriscina, et al.
The Oncologist
|
March 19, 2026
Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes and AI-guided treatment selection
Letizia Procaccio, Guido Giordano, Federico Nichetti, et al.
Page
of 3